{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T21:38:56Z","timestamp":1774301936228,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biomarkers guiding immunotherapy in non-small cell lung cancer (NSCLC) are limited. The glucose-to-lymphocyte ratio (GLR), integrating metabolic and immune status, has shown prognostic value in several cancers but has not been systematically evaluated in patients receiving PD-1 blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 837 patients with advanced or metastatic NSCLC treated with nivolumab across 21 oncology centers in Turkey (2015\u20132025). Baseline GLR was calculated from fasting glucose and absolute lymphocyte counts. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan\u2013Meier and compared with log-rank tests. Multivariate Cox regression models identified independent predictors. Receiver operating characteristic (ROC) analysis determined the optimal GLR cut-off for OS, which was subsequently applied to PFS analyses for consistency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The optimal GLR cut-off for mortality was \u226570.76 (AUC = 0.635, 95% CI: 0.597\u20130.674; p &amp;lt; 0.001). Patients with GLR &amp;lt;70.76 achieved significantly longer OS (median 24.1 vs 9.6 months; p &amp;lt; 0.001) and PFS (9.7 vs 5.8 months; p &amp;lt; 0.001) compared with those with GLR \u226570.76. In multivariate analysis, high GLR and poor ECOG performance status independently predicted worse OS. Prior thoracic radiotherapy was associated with improved outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline GLR is a practical, cost-effective biomarker that independently predicts OS in advanced NSCLC patients treated with nivolumab. Elevated GLR likely reflects metabolic dysfunction and impaired immune reserve, both unfavorable for PD-1 blockade efficacy. Prospective studies are warranted to validate GLR and define its role in clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1714533","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:50:17Z","timestamp":1770879017000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Mustafa","family":"Ersoy","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Kutahya Health Sciences University","place":["Kutahya, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Kefeli","sequence":"additional","affiliation":[{"name":"Kocaeli Universitesi Tip Fakultesi","place":["Izmit, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devrim","family":"Cabuk","sequence":"additional","affiliation":[{"name":"Kocaeli Universitesi Tip Fakultesi","place":["Izmit, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ertugrul","family":"Bayram","sequence":"additional","affiliation":[{"name":"Cukurova Universitesi Tip Fakultesi","place":["Adana, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duygu","family":"Bayir","sequence":"additional","affiliation":[{"name":"Eskisehir Osmangazi Universitesi Tip Fakultesi","place":["Eski\u015fehir, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oktay","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Erciyes Universitesi Tip Fakultesi","place":["Kayseri, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muslih","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[{"name":"Van Yuzuncu Yil Universitesi","place":["Van, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramazan","family":"Co\u015far","sequence":"additional","affiliation":[{"name":"Afyon Kocatepe Universitesi Tip Fakultesi","place":["Afyonkarahisar, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teoman","family":"Sakalar","sequence":"additional","affiliation":[{"name":"T\u00fcrkiye Cumhuriyeti (TC) Saglik Bakanligi Kahramanmaras Necip Fazil Sehir Hastanesi","place":["Dulkadiro\u011flu, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emel","family":"Mutlu","sequence":"additional","affiliation":[{"name":"T\u00fcrkiye Cumhuriyeti (TC) Saglik Bakanligi Corum Erol Olcok Egitim ve Arastirma Hastanesi","place":["\u00c7orum, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammet","family":"Cengiz","sequence":"additional","affiliation":[{"name":"Erciyes Universitesi Tip Fakultesi","place":["Kayseri, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Sahin","sequence":"additional","affiliation":[{"name":"T\u00fcrkiye Cumhuriyeti (TC) Saglik Bakanligi Kocaeli Sehir Hastanesi","place":["Izmit, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pervin","family":"Sanc\u0131","sequence":"additional","affiliation":[{"name":"T\u00fcrkiye Cumhuriyeti (TC) Saglik Bakanligi Kocaeli Sehir Hastanesi","place":["Izmit, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[{"name":"Afyon Kocatepe Universitesi Tip Fakultesi","place":["Afyonkarahisar, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdem","family":"Kolemen","sequence":"additional","affiliation":[{"name":"Kocaeli Universitesi Tip Fakultesi","place":["Izmit, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse","family":"Cengiz","sequence":"additional","affiliation":[{"name":"Erciyes Universitesi Tip Fakultesi","place":["Kayseri, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gozde","family":"Agdas","sequence":"additional","affiliation":[{"name":"Van Egitim ve Arastirma Hastanesi","place":["Van, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erkam","family":"Kocaaslan","sequence":"additional","affiliation":[{"name":"T\u00fcrkiye Cumhuriyeti (TC) Saglik Bakanligi Pendik Egitim ve Arastirma Hastanesi","place":["Pendik, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezgi","family":"Turkoglu","sequence":"additional","affiliation":[{"name":"Kartal Dr Lutfi Kirdar Sehir Hastanesi","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedat","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[{"name":"Kartal Dr Lutfi Kirdar Sehir Hastanesi","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berrak","family":"Mermeit","sequence":"additional","affiliation":[{"name":"Van Yuzuncu Yil Universitesi Tip Fakultesi","place":["Van, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Karakayal\u0131","sequence":"additional","affiliation":[{"name":"T\u00fcrkiye Cumhuriyeti (TC) Saglik Bakanligi Kocaeli Sehir Hastanesi","place":["Izmit, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayati","family":"Arvas","sequence":"additional","affiliation":[{"name":"Dicle Universitesi Tip Fakultesi","place":["Diyarbak\u0131r, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Mutlu","sequence":"additional","affiliation":[{"name":"Cukurova Universitesi Tip Fakultesi","place":["Adana, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedat","family":"Biter","sequence":"additional","affiliation":[{"name":"Cukurova Universitesi Tip Fakultesi","place":["Adana, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Havva","family":"Ye\u015fil \u00c7inkir","sequence":"additional","affiliation":[{"name":"Gaziantep Universitesi Tip Fakultesi","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet H.","family":"Y\u00fccel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Istanbul Medipol Universitesi Tip Fakultesi","place":["Beykoz, T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"Ca"},{"key":"B2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3892\/mco.2025.2837","article-title":"Treatment of advanced\u2212stage non\u2212small cell lung cancer: Current progress and a glimpse into the future","volume":"22","author":"Wang","year":"2025","journal-title":"Mol Clin Oncol"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.387","article-title":"Progresses in biomarkers for cancer immunotherapy","volume":"4","author":"Lin","year":"2023","journal-title":"MedComm"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer discovery"},{"key":"B9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/cancers14010109","article-title":"Comparative analysis of predictive biomarkers for PD-1\/PD-L1 inhibitors in cancers: developments and challenges","volume":"14","author":"Yang","year":"2021","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"crossref","first-page":"7689","DOI":"10.62347\/PZER7388","article-title":"Peripheral blood neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index values as prognostic predictors for non-small cell lung carcinoma","volume":"17","author":"Liu","year":"2025","journal-title":"Am J Trans Res"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002277","article-title":"Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score","volume":"9","author":"Dettorre","year":"2021","journal-title":"J ImmunoTherapy Cancer"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1427\u201347","DOI":"10.1007\/s11912-025-01718-7","article-title":"Host-related determinants of response to immunotherapy in non-small cell lung cancer: the interplay of body composition, metabolism, sex and immune regulation","volume":"27","author":"Santo","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-019-02457-y","article-title":"Enhanced glucose metabolism mediated by CD147 contributes to immunosuppression in hepatocellular carcinoma","volume":"69","author":"Li","year":"2020","journal-title":"Cancer Immunology Immunother"},{"key":"B14","article-title":"The Warburg effect: how does it benefit cancer cells","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"B15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13046-025-03318-6","article-title":"Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade","volume":"44","author":"Li","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B16","doi-asserted-by":"crossref","first-page":"10732748231202921","DOI":"10.1177\/10732748231202921","article-title":"Effect of peripheral blood lymphocytes on prognosis of multiple cancers","volume":"30","author":"Zhang","year":"2023","journal-title":"Cancer Control"},{"key":"B17","doi-asserted-by":"crossref","first-page":"1454393","DOI":"10.3389\/fimmu.2024.1454393","article-title":"Association between glucose to lymphocyte ratio and prognosis in patients with solid tumors","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fonc.2019.00347","article-title":"Prognostic value of gamma-glutamyl transpeptidase to lymphocyte count ratio in patients with single tumor size\u2264 5 cm hepatocellular carcinoma after radical resection","volume":"9","author":"Liao","year":"2019","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2022-0579","article-title":"The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer","volume":"19","author":"Hannarici","year":"2023","journal-title":"Future Oncol"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2021-0457","article-title":"The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib","volume":"17","author":"Y\u0131lmaz","year":"2021","journal-title":"Future Oncol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.21037\/tlcr-21-199","article-title":"Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1\/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis","volume":"10","author":"Zhou","year":"2021","journal-title":"Trans Lung Cancer Res"},{"key":"B22","article-title":"Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L) 1-based RCTs: a systematic review and meta-analysis","volume":"13","author":"Jimenez","year":"2025","journal-title":"J Immunotherapy Cancer"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New Engl J Med"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.7150\/thno.100036","article-title":"Harnessing glucose metabolism with nanomedicine for cancer treatment","volume":"14","author":"Wang","year":"2024","journal-title":"Theranostics"},{"key":"B26","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1186\/s12967-025-07272-x","article-title":"Lactate at the crossroads of tumor metabolism and immune escape: a new frontier in cancer therapy","volume":"23","author":"Dong","year":"2025","journal-title":"J Trans Med"},{"key":"B27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/intimm\/dxaa046","article-title":"Immune metabolism in PD-1 blockade-based cancer immunotherapy","volume":"33","author":"Kumar","year":"2021","journal-title":"Int Immunol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumor microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1416472","DOI":"10.3389\/fcell.2024.1416472","article-title":"Glycolysis in the tumor microenvironment: a driver of cancer progression and a promising therapeutic target","volume":"12","author":"Zhao","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1171274","DOI":"10.3389\/fimmu.2023.1171274","article-title":"Targeting glucose metabolism in cancer immunity and immunotherapy","volume":"14","author":"Feron","year":"2023","journal-title":"Front Media SA"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1835\u201357","DOI":"10.1158\/2159-8290.CD-24-1232","article-title":"Tumor-associated NK cells regulate distinct CD8+ T-cell differentiation program in cancer and contribute to resistance against immune checkpoint blockers","volume":"15","author":"Song","year":"2025","journal-title":"Cancer Discov"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6853","DOI":"10.3390\/ijms26146853","article-title":"The role of PI3K\/AKT\/mTOR signaling in tumor radiosensitivity and advances in inhibitor research","volume":"26","author":"Zhan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"crossref","first-page":"1074477","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"102074","DOI":"10.1016\/j.tranon.2024.102074","article-title":"Combination of radiotherapy and PD-L1 blockade induces abscopal responses in EGFR-mutated lung cancer through activating CD8+ T cells","volume":"48","author":"Xia","year":"2024","journal-title":"Trans Oncol"},{"key":"B35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13046-019-1192-1","article-title":"PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer","volume":"38","author":"Chen","year":"2019","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1714533\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:50:21Z","timestamp":1770879021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1714533\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1714533"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1714533","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1714533"}}